JP2022546110A5 - - Google Patents
Info
- Publication number
- JP2022546110A5 JP2022546110A5 JP2022513850A JP2022513850A JP2022546110A5 JP 2022546110 A5 JP2022546110 A5 JP 2022546110A5 JP 2022513850 A JP2022513850 A JP 2022513850A JP 2022513850 A JP2022513850 A JP 2022513850A JP 2022546110 A5 JP2022546110 A5 JP 2022546110A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- heterocyclyldiyl
- peg
- group
- aminoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895379P | 2019-09-03 | 2019-09-03 | |
| US62/895,379 | 2019-09-03 | ||
| PCT/US2020/049041 WO2021046112A1 (en) | 2019-09-03 | 2020-09-02 | Aminoquinoline compounds, immunoconjugates, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546110A JP2022546110A (ja) | 2022-11-02 |
| JP2022546110A5 true JP2022546110A5 (enExample) | 2023-08-30 |
Family
ID=72561946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513850A Pending JP2022546110A (ja) | 2019-09-03 | 2020-09-02 | アミノキノリン化合物、免疫複合体、及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220313835A1 (enExample) |
| EP (1) | EP4025254A1 (enExample) |
| JP (1) | JP2022546110A (enExample) |
| CN (1) | CN114630684A (enExample) |
| CA (1) | CA3148694A1 (enExample) |
| WO (1) | WO2021046112A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20230293716A1 (en) * | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| TW202440164A (zh) | 2022-12-13 | 2024-10-16 | 美商克林提克斯醫藥股份有限公司 | 生長抑素亞型-2受體（sst2r）靶向治療劑及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| NZ507557A (en) | 1998-05-06 | 2003-10-31 | Genentech Inc | Protein purification by ion exchange chromatography |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| US20190336615A1 (en) * | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
-
2020
- 2020-09-02 US US17/637,381 patent/US20220313835A1/en not_active Abandoned
- 2020-09-02 CA CA3148694A patent/CA3148694A1/en active Pending
- 2020-09-02 JP JP2022513850A patent/JP2022546110A/ja active Pending
- 2020-09-02 WO PCT/US2020/049041 patent/WO2021046112A1/en not_active Ceased
- 2020-09-02 EP EP20775464.9A patent/EP4025254A1/en active Pending
- 2020-09-02 CN CN202080073294.4A patent/CN114630684A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546110A5 (enExample) | ||
| JP2022549510A5 (enExample) | ||
| JP2022553702A5 (enExample) | ||
| JP2022537158A5 (enExample) | ||
| JP2023524271A5 (enExample) | ||
| JP2024523453A5 (enExample) | ||
| JP2022554094A5 (enExample) | ||
| JP2023527962A5 (enExample) | ||
| JP2023553421A5 (ja) | 抗ｃｅａ免疫複合体、及びその使用 | |
| JP2022527114A5 (enExample) | ||
| JP2020518669A5 (enExample) | ||
| JP2020515578A5 (enExample) | ||
| JP7208136B2 (ja) | Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー | |
| JP2020512270A5 (enExample) | ||
| JP2017095457A5 (enExample) | ||
| JP2022516427A5 (enExample) | ||
| JP2018511628A5 (enExample) | ||
| JP2023552792A5 (enExample) | ||
| JP2020530007A5 (enExample) | ||
| JP2015508074A5 (enExample) | ||
| JP2024533356A5 (enExample) | ||
| IL273387B2 (en) | Thylanstatin analogs | |
| JP2024501453A5 (enExample) | ||
| JP2023552791A5 (enExample) | ||
| JP2023505509A (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 |